常茂生物(00954.HK)簽署售後回租合同
格隆匯6月30日丨常茂生物(00954.HK)公告,於2025年6月30日,公司全資附屬常茂大連和出租人簽署了售後回租合同。據此,常茂大連同意以總對價約人民幣50,000,000元向出租人轉讓租賃資產,而常茂大連同意以總租金約人民幣57,531,114元租回租賃資產,爲期48個月。於租期屆滿後,在並無持續發生違約事件的前提下,且待收到售後回租合同項下所有租賃付款及其他應收款項後,常茂大連無須支付對價,出租人將按「現狀」基準將租賃資產的所有權轉回予常茂大連。
租賃資產指常茂大連向出租人出售順酐生產線若幹資產,並根據售後回租合同租回給常茂大連。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.